Objective: The purpose of this study was to determine the prevalence of bicuspid aortic valves (BAVs) and thoracic ascending aortic aneurysms (TAAs) in a retrospective cohort of patients treated for intracranial aneurysms (IAs).
The prevalence of intracranial aneurysms (IAs) in the general population is approximately 2% to 3%. 1 Recently, among 61 patients with bicuspid aortic valves (BAVs), 6 (9.8%) were found to harbor IAs. 2 This raises the possibility that patients with BAV should be screened for IA. However, this would have important and potentially costly consequences for the care of patients with BAV, who comprise approximately 1% to 2% of the general population. 3 Among the 6 patients with BAV, 5 also harbored a thoracic aortic aneurysm (TAA), raising the possibility that the association between BAV and IA was mediated by their common association with TAA. BAV is known to be associated with a significantly higher rate of aortic complications, including TAA, which increases in prevalence after diagnosis of BAV to greater than 20%. 4 Similarly, IA has been found to associate with aortic conditions, including coarctation of the aorta 5 and TAA. 6 Familial clustering and genetic linkage of aortic aneurysms and IAs have also been reported. [7] [8] [9] The purpose of this study was to test the hypothesis that the reported association between BAVs and IAs might instead be related to their common association with TAAs, by measuring the prevalence of TAAs and BAVs retrospectively in a large cohort of patients harboring a known IA.
METHODS Standard protocol approvals, registrations, and patient consents. Data collection was approved by the Washington University School of Medicine institutional review board. Informed consent was waived because of the retrospective nature of this study. treated for ruptured or unruptured nonmycotic IA at our institution between 2002 and 2011. Among these, we identified 317 patients with an echocardiogram, transthoracic (TTE) or transesophageal (TEE), in our hospital medical records that was sufficiently adequate to evaluate for BAV by report. TEE is more sensitive than TTE for identification of BAV, but by a relatively small amount (TEE 87% vs TTE 78%). 10 Echocardiography was performed for a variety of reasons in these patients, typically not in relation to their IA; no specific reason such as heart failure or syncope was more frequently seen than expected. Presence of BAV or TAA was determined by the echocardiogram report. When BAV or TAA was suspected, available echocardiogram images were reviewed for accuracy.
Among the 317 patients, we identified 82 patients who had chest CT in our medical records obtained for any reason; as for echocardiography, indications varied widely and no specific trend was identified. One of the authors reviewed these CTs and measured the largest diameter of the thoracic ascending aorta using multiplanar reconstruction without knowledge of the presence of TAA based on echocardiography. 11, 12 In these patients, TAA was defined according to established age-and sex-matched nomograms. 11 Thus, TAA presence in the total 317 patient cohort was defined as (1) TAA on echocardiogram report, (2) history of repaired TAA, or (3) TAA based on chest CT measurements. In cases when an unrepaired TAA was identified by either echocardiography or chest CT, but absent on the other, chest CT was preferentially used to define the presence of TAA given its ability to more completely evaluate the aorta. 13 History of hypertension or smoking was also assessed among these 82 individuals without knowledge of TAA status.
Confidence intervals (CIs) and comparisons between groups for subarachnoid hemorrhage, hypertension, smoking status, sex, and age were assessed by 2-sided proportion CIs, x 2 test, and Student t test, as implemented in the R statistical package (http://www.R-project.org).
RESULTS Patient characteristics and prevalence of BAVs and TAAs are shown in table 1 and figure 1. Prevalence of BAVs in the total cohort was 0.6% (95% CI 0.2%-2.2%). Prevalence of TAAs in the total cohort was 4.7% (95% CI 2.9%-7.6%). The 2 patients with BAV also had TAA, and one of the 2 had stented coarctation of the aorta. Another patient with TAA did not have BAV but also had stented coarctation of the aorta. Subarachnoid hemorrhage occurred in one of the 2 patients with BAV. Among patients with TAA, subarachnoid hemorrhage occurred in 6 patients (40% vs 55%, 2-tailed t test, p . 0.20).
Among the 82 patients with chest CT, 11 (13.4%, 95% CI 7%-23%) had TAA based on age-and sexmatched nomograms, more than expected (p , 0.03) (figure 2); the use of body-surface-area-based nomograms for these patients did not disqualify any as having TAA. 12 Males were more likely to have a TAA (p , 0.01). Patients with TAA were also more likely to have hypertension (11/11 vs 49/71, p 5 0.03), but not smoking history (p 5 0.40). No significant difference in subarachnoid hemorrhage or age was seen between those with and without TAA. Similarly, the prevalence of BAVs in our study is near that found in a normal population (1%-2%), 14 and both of the patients with BAV in our study also had TAA. Another recent report also found BAV in only 1 of 56 patients (1.8%) presenting with subarachnoid hemorrhage. 15 TAA, however, was associated with IA in our study. While prior estimates of TAAs in the general population have greatly varied (,1%-4.2%), 11, 12, 16, 17 these estimates are lower than the TAA prevalence in our cohort and are outside the 95% proportion CI for TAA prevalence among the 82 patients with chest CT (7%-23%). The increased prevalence of TAAs in patients with IAs is consistent with prior studies (table 2) .
The association between IA and TAA may be attributable to heritable and environmental factors. In particular, all of the patients with IA in this study identified by chest CT to have TAA also had hypertension, suggesting that this is likely a common etiologic factor for IA and TAA. Familial co-occurrence of TAA and IA also suggests a common genetic predisposition. 7 Polymorphisms in certain genes, e.g., those related to collagen and transforming growth factor b receptors, confer increased risk of cerebral and aortic aneurysms, as documented in a recent comprehensive review. 18 Genetic testing in young patients with aortic aneurysms or family history of aortopathies is occurring more frequently; similar testing may soon find a place in patients with IAs.
These results suggest that screening for BAVs in patients with IAs, or for IAs in patients with BAVs, is not warranted. Screening for TAAs in patients with IAs or IAs in patients with TAAs may be appropriate in a select population, although further study would be required to determine the subgroup of patients in whom such screening would be beneficial.
This study has several limitations. Retrospective selection of patients who underwent echocardiography may bias toward a larger prevalence of aortic disease. Conversely, the sensitivity of echocardiography is modest for BAV and TAA, and a minority of patients had chest CT, potentially causing us to underestimate the true prevalence of BAVs and TAAs. Despite using CT-defined age-and sex-based nomograms, the true prevalence of TAAs in a comparable normal population is unclear and varies according Several thoracic aortic diameters fall above the 95% confidence interval (n 5 11, 13.3%, more than expected, p , 0.03), showing that there is an increased prevalence of TAA in this cohort of 82 patients with IA. IA 5 intracranial aneurysm; TAA 5 thoracic aortic aneurysm. to the technique used. For clinical purposes, it is common to diagnose TAA when a diameter exceeds 4.0 cm, which was the case in most but not all the patients identified to have TAA by chest CT in this study. A prospective trial in patients with IAs and control subjects using imaging focused for evaluating TAAs and BAVs would surmount these issues.
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